Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1977 Aug;30(8):770–773. doi: 10.1136/jcp.30.8.770

Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII.

G R Milner, P J Holt, J Bottomley, J E Maciver
PMCID: PMC476544  PMID: 599192

Abstract

A patient is described who had an inhibitor to coagulation factor XIII associated with serum autoantibodies to certain tissues. The relationship of these abnormal findings to practolol therapy suggests that this was practolol-induced lupus erythematosus. Further investigations delineating the site of action of the inhibitor to factor XIII are reported.

Full text

PDF
770

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown P., Baddeley H., Read A. E., Davies J. D., McGarry J. Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet. 1974 Dec 21;2(7895):1477–1481. doi: 10.1016/s0140-6736(74)90218-9. [DOI] [PubMed] [Google Scholar]
  2. Castro O., Farber L. R., Clyne L. P. Circulating anticoagulants against factors IX and XI in systemic lupus erythematosus. Ann Intern Med. 1972 Oct;77(4):543–548. doi: 10.7326/0003-4819-77-4-543. [DOI] [PubMed] [Google Scholar]
  3. Lewis J. H., Szeto I. L., Ellis L. D., Bayer W. L. An acquired inhibitor to coagulation factor 13. Johns Hopkins Med J. 1967 Jun;120(6):401–407. [PubMed] [Google Scholar]
  4. Lorand L., Jacobsen A., Bruner-Lorand J. A pathological inhibitor of fibrin cross-linking. J Clin Invest. 1968 Feb;47(2):268–273. doi: 10.1172/JCI105723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lorand L., Maldonado N., Fradera J., Atencio A. C., Robertson B., Urayama T. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol. 1972 Jul;23(1):17–27. doi: 10.1111/j.1365-2141.1972.tb03455.x. [DOI] [PubMed] [Google Scholar]
  6. Lorand L., Urayama T., De Kiewiet J. W., Nossel H. L. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest. 1969 Jun;48(6):1054–1064. doi: 10.1172/JCI106061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. MARGOLIUS A., Jr, JACKSON D. P., RATNOFF O. D. Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore) 1961 May;40:145–202. [PubMed] [Google Scholar]
  8. McDevitt N. B., McDonagh J., Taylor H. L., Roberts H. R. An acquired inhibitor to factor XIII. Arch Intern Med. 1972 Nov;130(5):772–777. [PubMed] [Google Scholar]
  9. NUSSBAUM M., MORSE B. S. PLASMA FIBRIN STABILIZING FACTOR ACTIVITY IN VARIOUS DISEASES. Blood. 1964 May;23:669–678. [PubMed] [Google Scholar]
  10. Otis P. T., Feinstein D. I., Rapaport S. I., Patch M. J. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood. 1974 Dec;44(6):771–781. [PubMed] [Google Scholar]
  11. Raftery E. B., Denman A. M. Systemic lupus erythematosus syndrome induced by practolol. Br Med J. 1973 May 26;2(5864):452–455. doi: 10.1136/bmj.2.5864.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Robboy S. J., Lewis E. J., Schur P. H., Colman R. W. Circulating anticoagulants to factor VIII. Immunochemical studies and clinical response to factor VIII concentrates. Am J Med. 1970 Dec;49(6):742–752. doi: 10.1016/s0002-9343(70)80056-0. [DOI] [PubMed] [Google Scholar]
  13. Rosenberg R. D., Colman R. W., Lorand L. A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Br J Haematol. 1974 Feb;26(2):269–284. doi: 10.1111/j.1365-2141.1974.tb00472.x. [DOI] [PubMed] [Google Scholar]
  14. Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975 Mar 15;1(5958):595–598. doi: 10.1136/bmj.1.5958.595. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES